2025 A Focus on Intratumoral Therapies, Vaccines, & Cytokines

aci-intratumoral-therapies_-_Edited.png

thursday, may 8, 2025 | 11a.m.–3 P.M. ET
live via zoom webinar

Register Now

Join SITC and a panel of experts for an afternoon of in-depth education on all aspects of intratumoral therapies, vaccines, & cytokines. FREE for healthcare professionals, students, patients and patient advocates.

New for 2025

  • In-depth discussions on scientific and clinical aspects of personalized cancer vaccines, with an emphasis on the treatment of melanoma.
  • Presentations on cytokine therapies with special emphases on lessons learned from past studies and future directions of cytokine-based therapies.
The 2025 Advances in Cancer Immunotherapy™ series is supported, in part, through independent medical education grants from AstraZeneca, GSK, Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., and Replimune Inc. (supporters as of Mar. 12, 2025).

Program Organizers

Aurélien Marabelle, MD, PhD

Aurélien Marabelle, MD, PhD
Gustave Roussy

Patrick Ott, MD, PhD

Patrick Ott, MD, PhD
Dana-Farber Cancer Institute

Jamie Spangler, PhD

Jamie Spangler, PhD
Johns Hopkins University

Program Snapshot

Credits Available
Physician Education: 3.75 contact hours
Pharmacy Education: 3.75 contact hours (0.375 CEUs)
Nursing Education: 3.75 contact hours

Program Date & Location

Thursday, May 8, 2025 at 11 a.m.-3 p.m. ET
Live via Zoom Webinar

Program Cost

FREE for healthcare professionals, students, patients and patient advocates.

Register for A Focus on Intratumoral Therapies, Vaccines, & Cytokines >

Program Agenda

11–11:05 a.m.

 

Welcome and Relevant SITC Resources

11:05–11:35 a.m.

  

Clinical Aspects of Melanoma Personalized Vaccine Trial

Ryan Sullivan, MD - Massachusetts General Hospital

11:35–12:05 a.m.

 

Scientific Background of Personalized Cancer Vaccines 

Gregory Lizee, PhD - The University of Texas MD Anderson Cancer Center

12:05 a.m.–12:35 p.m.

 

Cytokine Therapies: Past Failures, Future Directions 

Adil Daud, MD - UCSF

Tom Malek, PhD - University of Miami

12:35–1:05 p.m.

 

Intratumoral Therapies, In Situ Vaccines 

Michael Wong, MD, PhD - The University of Texas MD Anderson Center Cancer

1:05–1:20 p.m.

 

Break 

1:20–1:35 p.m.

 

Cancer Immunotherapy in Practice: Cytokines

Adi Diab, MD - The University of Texas MD Anderson Center

1:35-1:50 p.m.

 

Cancer Immunotherapy in Practice: Intratumoral Therapies

Nicole LeBoeuf, MD, MPH, FAAD – Dana-Farber Cancer Institute

1:50-2:05 p.m.

 

Cancer Immunotherapy in Practice: irAEs

Elad Sharon, MD, MPH - Dana-Farber Cancer Institute

2:05–3 p.m

 

Faculty Panel

3 p.m

 

Closing Remarks

    SITC ACI Series

    This program is part of the SITC ACI series. View below to explore more programs in the 2025 ACI series.

    Program Details

    Target Audience

    The Advances in Cancer Immunotherapy™ (ACI) programs aim to reach practicing clinical oncologists, nurses, nurse practitioners, advanced practitioners, pharmacists, emergency physicians, and other allied health professionals who wish to learn the basic principles of cancer immunotherapy and the most up-to-date clinical data for these treatments, in a multitude of disease states/therapeutic areas, in order to inform and integrate into their own clinical practice. In-training oncologists and hospital administrators will also find the program beneficial.

    Case Study Submission Information

    As part of the program, registrants are encouraged to submit case studies for expert review during the case study panel concluding the program. If you are interested in taking advantage of this opportunity, please review and sign the linked case study guidelines, and return your case study and signed guidelines to education@sitcancer.org.

    Program Learning Objectives

    • Describe the mechanisms of intratumoral therapies, vaccines, and cytokines.
    • Summarize recent updates in the use of intratumoral therapies, vaccines, and cytokines clinically.
    • Outline common toxicities with intratumoral therapies, vaccines and cytokines and their management.

    Accreditation Information

    Joint Accreditation Statement

    thumbnail image In support of improving patient care, this activity has been planned and implemented by Partners for Advancing Clinical Education (PACE) and the Society for Immunotherapy of Cancer (SITC). PACE is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC)

    Successful ABIM_Logo.jpgcompletion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 3.75 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

    Physician Continuing Medical Education

    PACE designates this live activity for a maximum of 3.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Continuing Pharmacy Education

    PACE designates this continuing education activity for 3.75 contact hour(s) (0.375 CEUs) of the Accreditation Council for Pharmacy Education.

    Continuing Nursing Education

    The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 3.75 contact hours. Pharmacotherapy contact hours for Advanced Practice Registered Nurses will be designated on your certificate.

    Disclosures

    Disclosure of Conflicts of Interest

    PACE requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. All relevant financial relationships are mitigated according to PACE policies.

    Avoid Fraudulent ACI Websites

    Recently, the SITC office received communication about a fraudulent registration website for one of our ACI programs. To help ensure others don’t mistakenly register on an unauthorized, third-party website, we're proactively informing you to ensure you’re able to safely register for the event through the official SITC website, and so that you can confirm the communication you receive is truly from SITC.

    All official forthcoming ACI registration information will come from an email address ending in @sitcancer.org. If you have any questions, please contact the SITC office at events@sitcancer.org or 414-271-2456.

    SITC's Clinical Practice Guideline (CPG) Resources

    Find information regarding disease-specific treatment algorithms and recommended administration of FDA-approved cancer immunotherapies. The guidelines are reviewed by expert panels on a recurring basis to account for newly available clinical trial data and FDA approvals.

     Relevant Guidelines

     Mini-Modules

     Featured Webinars

     The 2025 ACI series is jointly provided by Partners for Advancing Clinical Education and the Society for Immunotherapy of Cancer.